Generic Name and Formulations:
Methenamine 81mg, sodium biphosphate 40.8mg, phenyl salicylate 32.4mg, methylene blue 10.8mg, hyoscyamine sulfate 0.12mg; tabs.
Indications for URELLE:
Treatment of symptoms of irritative voiding. Relief of local symptoms due to lower UTIs or diagnostic procedures.
1 tab 4 times daily.
≤6yrs: not recommended. >6yrs: individualize dose.
Cardiac disease. GI or GU obstruction. Glaucoma. Myasthenia gravis.
Maintain acid urine and adequate hydration. Gastric ulcers. Discolors urine/feces. Discontinue if rapid pulse, dizziness, or blurred vision occurs. Elderly. Pregnancy (Cat.C). Nursing mothers.
Urinary tract analgesic/antispasmodic/antiseptic.
Allow at least 2 hours after ketoconazole. May be potentiated by antimuscarinics, antimyasthenics, MAOIs, opioids. May be antagonized by thiazide diuretics, urinary alkalinizers. Separate dosing of antacids, antidiarrheals by 1 hour. May reduce absorption of other drugs. Sulfonamides precipitate with formaldehyde in urine; avoid concomitant use.
Rapid pulse, flushing, blurred vision, dizziness, shortness of breath, acute urinary retention, difficult micturition, dry mouth, nausea, vomiting.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline